Knight Therapeutics Inc., a leading Pan American specialty pharmaceutical company (“Knight”), announced the signing of a new exclusive distribution agreement with Gilead Sciences, Inc. (“Gilead”) ) for the marketing of AmBisome® (liposomal amphotericin B) in Brazil. The agreement will enter into force as of 1 st January 2021. “We are pleased to continue this already established partnership and are very grateful to Gilead for the continued trust in the Knight team,” said Samira Sakhia, President and COO of Knight. Our Brazilian team launched AmBisome in Brazil over 20 years ago and we are excited to continue the great work we have done with patients and physicians ”. "The signing of this new agreement extends the historic collaboration between Gilead and Grupo Biotoscana (" GBT ") and confirms Knight's assessment of the GBT acquisition," said Amal Khouri, vice president of business development at Knight. “Gilead values ​​the ongoing partnership with GBT to meet medical needs in Brazil,” said Ahmed Afifi, vice president and head of the Latin America region at Gilead Sciences. With this new agreement, we are pleased to continue our cooperation with the extended GBT / Knight team to enable Brazilian patients to benefit from AmBisome
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!